Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
COEPW | US
-0.00
-9.13%
Healthcare
Biotechnology
30/06/2024
18/10/2024
0.02
0.01
0.02
0.01
Coeptis Therapeutics Holdings Inc. a biopharmaceutical company develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK a cell therapy for the treatment of CD38-related cancers including multiple myeloma chronic lymphocytic leukemia and acute myeloid leukemia; SNAP-CAR a CAR T cell therapy platform co-administered with tagged tumor-specific antibodies to potentially target different tumor types including hematological malignancies and solid tumors; and CD38-Diagnostic an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics Holdings Inc. is headquartered in Wexford Pennsylvania.
View LessLow Debt to Asset (< 0.2)
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Low negative Beta, possible Low Liquidity (< -0.4)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
131.2%1 month
187.2%3 months
378.6%6 months
396.6%-
-
-
0.25
0.15
-
-
-
-23.93M
-
-
-
-
-
-
-1.45K
-
-
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.01
Range1M
0.02
Range3M
0.03
Rel. volume
0.12
Price X volume
128.81
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Vanda Pharmaceuticals Inc | VNDA | Biotechnology | 4.91 | 0 | 3.70% | n/a | |
Viking Therapeutics Inc | VKTX | Biotechnology | 65.8 | 0 | 1.83% | n/a | |
VIRACTA THERAPEUTICS INC | VIRX | Biotechnology | 0.2298 | 0 | 3.14% | n/a | |
VINC | VINC | Biotechnology | 0.38 | 0 | 0.66% | n/a | |
Vigil Neuroscience Inc. Common Stock | VIGL | Biotechnology | 3.96 | 0 | -0.75% | n/a | |
Verve Therapeutics Inc. Common Stock | VERV | Biotechnology | 5.65 | 0 | 3.48% | n/a | |
Vera Therapeutics Inc. Class A Common Stock | VERA | Biotechnology | 41.16 | 0 | 3.18% | n/a | |
Veracyte Inc | VCYT | Biotechnology | 34.44 | 0 | 0.38% | n/a | |
Vaccinex Inc - Ordinary Shares | VCNX | Biotechnology | 2.53 | 0 | 0.40% | n/a | |
Vericel Corporation | VCEL | Biotechnology | 41.66 | 0 | 2.43% | n/a |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 3.92 | 0 | -8.84% | n/a | |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.4801 | 0 | -10.26% | n/a | |
Urban One Inc | UONEK | Broadcasting - Radio | 1.045 | 0 | -2.34% | n/a | |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 14.82 | 0 | 1.93% | n/a | |
Winnebago Industries Inc | WGO | Recreational Vehicles | 60.38 | 0 | 0.37% | n/a |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | - | 0.53 | - |
Ent. to Revenue | - | 4,005.99 | - |
PE Ratio | - | 40.42 | - |
Price to Book | - | 15.30 | - |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 378.62 | 72.92 | Riskier |
Debt to Equity | 0.25 | -1.24 | Expensive |
Debt to Assets | 0.15 | 0.25 | Cheaper |
Market Cap | - | 3.78B | - |